XORTX Therapeutics (XRTX) Earnings Date & Reports

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

XRTX is expected to report earnings to fall 58.70% to -27 cents per share on May 01

XORTX Therapeutics XRTX Stock Earnings Reports

Q4'23

Est.

$-0.28

Q3'23

Missed

by $0.44

Q2'23

Missed

by $0.64

Q1'23

Missed

by $0.84

Q4'22

Missed

by $2.11

The last earnings report on November 15 showed earnings per share of -67 cents, missing the estimate of -22 cents. With 1.33K shares outstanding, the current market capitalization sits at 3.19M.

View a ticker or compare two or three

Compare

XRTX